Our distinct approach is to grow value in our portfolio companies by not just advising but doing. We take material equity stakes in spin-out companies in return for providing a range of commercialisation services through the support of our experienced team.
These services include providing strategic direction, proactive, hands-on help with technology and business development and in finding funds from investors, industry partners and grant schemes.
Of vital importance to the way we work is involving relevant industry partners at an early state of technology development. This ensures the technology meets real world needs and demands, and can be scaled up effectively for volume production.
Alusid’s SilicaStone is a new material made from recycled glass and ceramics, sourced from industrial waste, to provide an attractive and adaptable alternative to natural stone. A spin-out from the Silicate Research Unit of the University of Central Lancashire, Alusid was formed to license and commercialise the process to transform waste materials into a highly durable and functional material with applications in the construction industry, such as tiles and other surfaces for use on feature walls and interiors. The company was co-founded by Dr Alasdair Bremner, who now works for the business full time, and Professor David Binns, Head of Contemporary Ceramics at UCLAN. Alusid has secured raw materials supply agreements and its pilot plant is fully operational.
You can learn more here: http://www.alusid.co.uk/
TARSIS TECHNOLOGY LIMITED
Tarsis Technology is developing and commercialising technology created by Dr. David Fairen-Jimenez, a Royal Society University Research Fellow at the Department of Chemical Engineering and Biotechnology at the University of Cambridge, and his research team. The technology allows slower and more controlled delivery of active ingredients using metal-organic frameworks (MOFs).
NANDI PROTEINS LIMITED
Founded by chief technology officer Dr Lydia Campbell, Nandi specialises in developing a platform technology which improves the functional properties of proteins in food manufacturing. When its patented process technology is applied to naturally occurring proteins such as whey and egg, which are used extensively as ingredients in food manufacture, the functional properties of these proteins are improved, creating a product which can replace (in whole or in part) sugars, fats and additives (specifically emulsifiers, commonly E471) in the end-product. Food manufacturers are under increasing pressure to respond to rising global obesity rates and the associated cost, both human and economic, of diet-related ill-health.
Nandi’s product can reduce or replace sugars, fats and additives in foods without negatively affecting taste and texture.
PoreXpert was formed to accelerate the commercialisation activity of Professor Peter Matthews Environmental and Fluid Modelling Group which develops software for modelling porous systems. In close partnership with Thermo Scientific, Porometer nv and MicrotracBEL Inc, the company provides software, for sale or through consultancy, which generates a three-dimensional simulation of the voids within a sample, based on porometry, porosimetry or, less directly, electron or optical microscopy. The resulting structure can then be used to simulate properties that include depth filtration efficiency and absolute permeability. The software also has a ‘targeted modification’ feature which allows the user to make alterations to the structure virtually, so they can optimise the properties of a given material in a cost effective manner or simulate future effects such as weathering.
Exscientia is at the forefront of artificial intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, it is the first company to automate drug design, surpassing conventional approaches. Its innovative platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy.
PULSIV SOLAR LIMITED
PulsiV, led by Associate Professor Dr. Zaki Ahmed, is developing patented technology which significantly improves energy efficiency. The PulsiV technology harnesses the principles of high frequency, pulsed-power extraction techniques, establishing a new method of harvesting more efficient energy for a wide range of applications from commercial solar farms, to the power converters used in a huge range of consumer devices, such as televisions, mobile phones and laptops.
Learn more here: http://www.pulsiv.co.uk
THE VACCINE GROUP LIMITED
The Vaccine Group, led by Dr Michael Jarvis, develops herpesvirus-based vaccines suitable for use in animals. They protect human health by targeting animal species carrying disease which can be transmitted to people. Such zoonotic diseases include Ebola, SARS, AIDS, Marburg viruses and swine and bird flus. More information on Dr Jarvis’ work can be found here: http://www.thevaccinegroup.co.uk
CAMBRIDGE SIMULATION SOLUTIONS LIMITED
Cambridge Simulation Solutions develops a method to simulate and control complex discontinuous processes, such as the way neural transmitters work in the brain. There is a wide range of potential industrial applications for the University of Cambridge spin out to explore.
Sector – IT / Life Sciences
Source – University of Cambridge
Molendotech is developing a rapid assay to screen water for faecal contamination and other harmful bacteria. Current tests on the market may take hours or even days to show results because samples need to be sent to a laboratory. Molendotech's technology can be used on site and typically produces results in under 15 minutes. Rapid, point-of-use testing to determine water quality enables more informed decision-making about the use of water and significantly improves the ability to identify and track pollution sources. The company is working with Palintest, a subsidiary of FTSE 100 group Halma plc to commercialise the technology.
Sector – Life Sciences
Source – University of Plymouth
Neil Crabb is Chief Executive of Frontier IP. He co-founded Sigma Capital Group plc and has considerable experience as an investor and director of a wide range of technology and university spin-out companies. He was previously an investment manager at Duncan Lawrie Ltd. with responsibility for a range of managed portfolios investing in smaller UK companies and unquoted technology companies, prior to which he spent four years with Equitable Life Assurance Soc., latterly as investment analyst managing investments in UK small companies and larger stocks in the electronics sector.
Jackie is the Group's Chief Operating Officer, supporting the Chief Executive in the delivery of the Group's objectives. She has substantial experience of the university IP and venture capital industries and has been working with Frontier IP since its inception to help develop new and existing commercialisation relationships. Jackie spent nearly ten years at Sigma Capital Group plc, latterly as Corporate Development Director, where she was responsible for structuring and setting up venture funds and university partnerships. Prior to Sigma, Jackie spent 12 years with Bank of Scotland. She has an MA in Psychology.
Jim is Finance Director and Company Secretary of Frontier IP. He has over 25 years' experience in senior financial positions and a wide range of commercial experience including venture capital funded small/medium-sized enterprises and start-up companies. He was latterly interim Finance Director at The One Place Capital Limited, an online technology start-up. He qualified as a chartered accountant with KPMG and holds a degree in Accounting and Finance from Heriot Watt University, Edinburgh.
Matt is Director of Commercialisation. He has over 23 years’ experience in technology, product and service innovation, business development and marketing. In his previous role he was Head of Innovation, AB Sugar, part of FTSE 100 group AB Foods. He also has extensive experience working with university partners.
Andrew, a former deputy city Editor for the Daily Express, was a journalist for more than 20 years before moving into financial services where he worked in communications and marketing. He studied Modern History at the University of Oxford.
David is Portfolio Director at Frontier IP and is responsible for specific projects within the Group’s portfolio in line with his expertise. David has 25 years' experience in developing technology from concept through to commercialisation. He previously worked for Optos plc, the retinal imaging company, where he was instrumental in building the business from start-up, serving on the board until its flotation on the London Stock Exchange.
Rui is a Portfolio Manager at Frontier IP, focused on the energy sector. He has over 5 years' with EDP (Energias de Portugal) in renewables and energy efficiency and was latterly Senior Associate at Fidelity Worldwide Investment. He also brings experience of company creation, management and funding.
Paul is a Portfolio Executive at Frontier IP and based in Cambridge. He has over 15 years’ experience with Ciba-Geigy in the commercialisation of new technology for semi-conductors and electronics. As Director and General Manager for 3 global businesses during that time he brings real practical experience of business leadership. Most recently as a member of the University of Cambridge he has led the commercialisation of a number of innovative technologies.
Sara is a Commercialisation Officer at Frontier IP. She has over 6 years' experience of technology transfer in different Portuguese universities, supporting R&D groups developing technology into spinout companies. She also worked as business development manager for a startup in the US. Sara holds a degree in Molecular Biology and Genetics and a masters in Economics and Management of Science, Technology and Innovation.
Ignacio holds a degree in Computer Science from Universidad de Granada. His specialism is intelligent systems, and his chief interests are machine learning, metaheuristics and computer vision, particularly computer vision applied to medical imaging. He joined Frontier to foster technical development for projects within Frontier itself and also extend his expertise to portfolio companies.
Janice is the Accounts and Administration assistant, working on the accounts for Frontier and the portfolio companies. She has a broad range of experience working in the finance teams of large corporate companies such as IQVIA as well as small non-profit organisations. Janice holds a Diploma in Accounting and Business and is currently studying toward becoming a certified accountant with ACCA.
Flavia provides executive assistance to Neil Crabb, CEO of Frontier IP. She holds a degree in Translation (Portuguese and English) from Universidade do Sagrado Coracao, Brazil. She also has an Executive Secretary Diploma from Pitman Training in London. Flavia has over six years' experience assisting senior managers in various industries.
Janet has strong experience in finance and administration in companies commercialising research. While working for Edinburgh University in the early 2000s she was seconded to work on the launch of the spin-out Rhetorical, the highly regarded text-to-speech developer, and subsequently joined the company. She moved in 2005 to MTEM Ltd, another Edinburgh spin-out, this time in the very fast-moving environment of oil and gas services. Here she worked up to, through and after the sale of the company to Norway’s PGS, as work continued on developing the patented technology. She has also held posts Hyaltech Ltd and Napier University, Edinburgh.
Andrew Richmond is Non-Executive Chairman of Frontier IP. Andrew has substantial experience of the healthcare, stockbroking and private equity industries. He is Chairman of Hub North Scotland and was previously a Lay Member of the Court of the University of Dundee.
Campbell is a Non-Executive Director of Frontier IP. Campbell, who is past Chairman and currently a member of the Board of the UK Pharmaceutical Licensing Group, has worked in the UK pharmaceutical industry for approximately 35 years. The last 17 years of his career were in business development at AstraZeneca, the global research-based biopharmaceutical company, latterly as Executive Business Development Director within the company's central Business Development function. He led strategic collaboration and licensing activities at the unit, driving multiple technology and oncology therapy area collaborations and product licensing deals, including high profile and innovative agreements. Before his involvement in business development, Campbell worked in senior level scientific roles in cardiovascular drug discovery at AstraZeneca, and earlier at Beecham Pharmaceuticals (now GSK).
Mike is a Non-Executive Director of Frontier IP. Mike has almost 30 years' experience in investment management and particular expertise in technology, life sciences and clean technology. He is currently Partner of Accretion Capital LLP and a Director of Cygna Negra Limited and Cygna Negra Malta Limited. He is also an Advisory Board Member of V2R, the US technology transfer venture company. Prior to these roles, in 1995, he founded asset management company, Reabourne Technology Investment Management Limited, where he was also Chief Investment Officer. For nine years until 2009, he was also a member of the techMARK Advisory Committee.